Fn14 in podocytes and proteinuric kidney disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 12, 2013, Pages 2232-2243

  Sanchez Niño, Maria Dolores ^a   Poveda, Jonay ^b   Sanz, Ana Belen ^a   Mezzano, Sergio ^c   Carrasco, Susana ^b   Fernandez Fernandez, Beatriz ^b   Burkly, Linda C ^d   Nair, Viji ^e   Kretzler, Matthias ^e   Hodgin, Jeffrey B ^f   Ruiz Ortega, Marta ^b   Selgas, Rafael ^a   Egido, Jesus ^b   Ortiz, Alberto ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b Section of Nephrology   (Spain)

^c UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^d BIOGEN   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Fn14; Focal segmental glomerulosclerosis; Kidney; Podocyte; Proteinuria; TWEAK

Indexed keywords

FN14 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PARTHENOLIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADENOVIRUS; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE REPORT; CELL COUNT; CELL CULTURE; CONTROLLED STUDY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GENE CONTROL; GLOMERULITIS; GLOMERULUS; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; KNOCKOUT MOUSE; MACROPHAGE; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; TRANSCRIPTOMICS; WILD TYPE;

EID: 84884345439     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.08.010     Document Type: Article

References (67)

1. Boonstra J.G., van der Woude F.J., Wever P.C., Laterveer J.C., Daha M.R. K.C. van, expression and function of Fas (CD95) on human renal tubular epithelial cells. J. Am. Soc. Nephrol. 1997, 8:1517-1524.
2. Brown F.G., Nikolic-Paterson D.J., Hill P.A., Isbel N.M., Dowling J., Metz C.M., Atkins R.C. Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J. Am. Soc. Nephrol. 2002, 13(Suppl. 1):S7-S13.
3. Burkly L.C., Michaelson J.S., Hahm K., Jakubowski A., Zheng T.S. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007, 40:1-16.
4. Burt D., Salvidio G., Tarabra E., Barutta F., Pinach S., Dentelli P., Camussi G., Perin P.C., Gruden G. The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. Am. J. Pathol. 2007, 171:1789-1799.
5. Campbell S., Burkly L.C., Gao H.X., Berman J.W., Su L., Browning B., Zheng T., Schiffer L., Michaelson J.S., Putterman C. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J. Immunol. 2006, 176:1889-1898.
6. Chicheportiche Y., Bourdon P.R., Xu H., Hsu Y.M., Scott H., Hession C., Garcia I., Browning J.L. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 1997, 272:32401-32410.
7. Chow F., Ozols E., Nikolic-Paterson D.J., Atkins R.C., Tesch G.H. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004, 65:116-128.
8. Cohen C.D., Frach K., Schlondorff D., Kretzler M. Quantitative gene expression analysis in renal biopsies: a novel protocol for a high-throughput multicenter application. Kidney Int. 2002, 61:133-140.
9. D'Agati V.D. Podocyte injury in focal segmental glomerulosclerosis: lessons from animal models (a play in five acts). Kidney Int. 2008, 73:399-406.
10. D'Agati V.D. The spectrum of focal segmental glomerulosclerosis: new insights. Curr. Opin. Nephrol. Hypertens. 2008, 17:271-281.
11. D'Agati V.D., Fogo A.B., Bruijn J.A., Jennette J.C. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am. J. Kidney Dis. 2004, 43:368-382.
12. D'Agati V.D., Kaskel F.J., Falk R.J. Focal segmental glomerulosclerosis. N. Engl. J. Med. 2011, 365:2398-2411.
13. Darisipudi M.N., Kulkarni O.P., Sayyed S.G., Ryu M., Migliorini A., Sagrinati C., Parente E., Vater A., Eulberg D., Klussmann S., Romagnani P., Anders H.J. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am. J. Pathol. 2011, 179:116-124.
14. Eardley K.S., Zehnder D., Quinkler M., Lepenies J., Bates R.L., Savage C.O., Howie A.J., Adu D., Cockwell P. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int. 2006, 69:1189-1197.
15. Fernandez F.B., Elewa U., Sanchez-Nino M.D., Rojas-Rivera J.E., Martin-Cleary C., Egido J., Ortiz A. 2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials. Minerva Med. 2012, 103:219-234.
16. Gao H.X., Campbell S.R., Burkly L.C., Jakubowski A., Jarchum I., Banas B., Saleem M.A., Mathieson P.W., Berman J.W., Michaelson J.S., Putterman C. TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine 2009, 46:24-35.
17. Giunti S., Barutta F., Perin P.C., Gruden G. Targeting the MCP-1/CCR2 system in diabetic kidney disease. Curr. Vasc. Pharmacol. 2010, 8:849-860.
18. Gu L., Hagiwara S., Fan Q., Tanimoto M., Kobata M., Yamashita M., Nishitani T., Gohda T., Ni Z., Qian J., Horikoshi S., Tomino Y. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol. Dial. Transplant. 2006, 21:299-313.
19. Gutwein P., Abdel-Bakky M.S., Schramme A., Doberstein K., Kampfer-Kolb N., Amann K., Hauser I.A., Obermuller N., Bartel C., Abdel-Aziz A.A., El Sayed el S.M., Pfeilschifter J. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am. J. Pathol. 2009, 174:2061-2072.
20. Hartner A., Klanke B., Cordasic N., Amann K., Schmieder R.E., Veelken R., Hilgers K.F. Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone-acetate-salt hypertension. J. Hypertens. 2009, 27:376-385.
21. Hehner S.P., Hofmann T.G., Droge W., Schmitz M.L. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J. Immunol. 1999, 163:5617-5623.
22. Hodgin J.B., Borczuk A.C., Nasr S.H., Markowitz G.S., Nair V., Martini S., Eichinger F., Vining C., Berthier C.C., Kretzler M., D'Agati V.D. A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am. J. Pathol. 2010, 177:1674-1686.
23. Hotta K., Sho M., Yamato I., Shimada K., Harada H., Akahori T., Nakamura S., Konishi N., Yagita H., Nonomura K., Nakajima Y. Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int. 2011, 79:179-188.
24. Imakiire T., Kikuchi Y., Yamada M., Kushiyama T., Higashi K., Hyodo N., Yamamoto K., Oda T., Suzuki S., Miura S. Effects of renin-angiotensin system blockade on macrophage infiltration in patients with hypertensive nephrosclerosis. Hypertens. Res. 2007, 30:635-642.
25. Jain M., Jakubowski A., Cui L., Shi J., Su L., Bauer M., Guan J., Lim C.C., Naito Y., Thompson J.S., Sam F., Ambrose C., Parr M., Crowell T., Lincecum J.M., Wang M.Z., Hsu Y.M., Zheng T.S., Michaelson J.S., Liao R., Burkly L.C. A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 2009, 119:2058-2068.
26. Jakubowski A., Ambrose C., Parr M., Lincecum J.M., Wang M.Z., Zheng T.S., Browning B., Michaelson J.S., Baetscher M., Wang B., Bissell D.M., Burkly L.C. TWEAK induces liver progenitor cell proliferation. J. Clin. Invest. 2005, 115:2330-2340.
27. Johnson W.E., Li C., Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007, 8:118-127.
28. Justo P., Sanz A.B., Sanchez-Nino M.D., Winkles J.A., Lorz C., Egido J., Ortiz A. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int. 2006, 70:1750-1758.
29. Kang Y.S., Lee M.H., Song H.K., Ko G.J., Kwon O.S., Lim T.K., Kim S.H., Han S.Y., Han K.H., Lee J.E., Han J.Y., Kim H.K., Cha D.R. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int. 2010, 78:883-894.
30. Katsuyama K., Fujinaka H., Yamamoto K., Nameta M., Yaoita E., Yoshida Y., Tomizawa S., Uchiyama M., Yamamoto T. Expression of the chemokine fractalkine (FKN/CX3CL1) by podocytes in normal and proteinuric rat kidney glomerulus. Nephron Exp. Nephrol. 2009, 113:e45-e56.
31. Lan H.Y., Yang N., Nikolic-Paterson D.J., Yu X.Q., Mu W., Isbel N.M., Metz C.N., Bucala R., Atkins R.C. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int. 2000, 57:499-509.
32. Lee E.Y., Chung C.H., Khoury C.C., Yeo T.K., Pyagay P.E., Wang A., Chen S. The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am. J. Physiol. Renal Physiol. 2009, 297:F85-F94.
33. Li Y., Tucci M., Narain S., Barnes E.V., Sobel E.S., Segal M.S., Richards H.B. Urinary biomarkers in lupus nephritis. Autoimmun. Rev. 2006, 5:383-388.
34. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
35. Lorz C., Ortiz A., Justo P., Gonzalez-Cuadrado S., Duque N., Gomez-Guerrero C., Egido J. Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. J. Am. Soc. Nephrol. 2000, 11:1266-1277.
36. Mezzano S.A., Barria M., Droguett M.A., Burgos M.E., Ardiles L.G., Flores C., Egido J. Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int. 2001, 60:1366-1377.
37. Michaelson J.S., Wisniacki N., Burkly L.C., Putterman C. Role of TWEAK in lupus nephritis: a bench-to-bedside review. J. Autoimmun. 2012, 39:130-142.
38. Molano A., Lakhani P., Aran A., Burkly L.C., Michaelson J.S., Putterman C. TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunol. Lett. 2009, 125:119-128.
39. Mundel P., Kriz W. Cell culture of podocytes. Exp. Nephrol. 1996, 4:263-266.
40. Nam B.Y., Paeng J., Kim S.H., Lee S.H., Kim d.H., Kang H.Y., Li J.J., Kwak S.J., Park J.T., Yoo T.H., Han S.H., Kim D.K., Kang S.W. The MCP-1/CCR2 axis in podocytes is involved in apoptosis induced by diabetic conditions. Apoptosis 2012, 17:1-13.
41. Neale T.J., Ruger B.M., Macaulay H., Dunbar P.R., Hasan Q., Bourke A., Murray-McIntosh R.P., Kitching A.R. Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am. J. Pathol. 1995, 146:1444-1454.
42. Niemir Z.I., Stein H., Dworacki G., Mundel P., Koehl N., Koch B., Autschbach F., Andrassy K., Ritz E., Waldherr R., Otto H.F. Podocytes are the major source of IL-1 alpha and IL-1 beta in human glomerulonephritides. Kidney Int. 1997, 52:393-403.
43. Ortiz A., Sanz A.B., Munoz G.B., Moreno J.A., Sanchez Nino M.D., Martin-Ventura J.L., Egido J., Blanco-Colio L.M. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev. 2009, 20:251-258.
44. Ping D., Boekhoudt G.H., Rogers E.M., Boss J.M. Nuclear factor-kappa B p65 mediates the assembly and activation of the TNF-responsive element of the murine monocyte chemoattractant-1 gene. J. Immunol. 1999, 162:727-734.
45. Prodjosudjadi W., Gerritsma J.S., van Es L.A., Daha M.R., Bruijn J.A. Monocyte chemoattractant protein-1 in normal and diseased human kidneys: an immunohistochemical analysis. Clin. Nephrol. 1995, 44:148-155.
46. Ronco P., Debiec H. Pathogenesis of membranous nephropathy: recent advances and future challenges. Nat. Rev. Nephrol. 2012, 8:203-213.
47. Rovin B., Jayne D., Mysler E., Wofsy D., Wisniacki N. ATLAS Study: Anti-TWEAK in Lupus Nephritis Study 2011, (abstract presented at ASN).
48. Saito T., Yusa A., Soma J., Ootaka T., Sato H., Ito S. Significance of leukocyte infiltration in membranous nephropathy with segmental glomerulosclerosis. Nephron 1998, 80:414-420.
49. Sanchez-Nino M.D., Sanz A.B., Ihalmo P., Lassila M., Holthofer H., Mezzano S., Aros C., Groop P.H., Saleem M.A., Mathieson P.W., Langham R., Kretzler M., Nair V., Lemley K.V., Nelson R.G., Mervaala E., Mattinzoli D., Rastaldi M.P., Ruiz-Ortega M., Martin-Ventura J.L., Egido J., Ortiz A. The MIF receptor CD74 in diabetic podocyte injury. J. Am. Soc. Nephrol. 2009, 20:353-362.
50. Sanchez-Nino M.D., Sanz A.B., Lorz C., Gnirke A., Rastaldi M.P., Nair V., Egido J., Ruiz-Ortega M., Kretzler M., Ortiz A. BASP1 promotes apoptosis in diabetic nephropathy. J. Am. Soc. Nephrol. 2010, 21:610-621.
51. Sanz A.B., Justo P., Sanchez-Nino M.D., Blanco-Colio L.M., Winkles J.A., Kreztler M., Jakubowski A., Blanco J., Egido J., Ruiz-Ortega M., Ortiz A. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J. Am. Soc. Nephrol. 2008, 19:695-703.
52. Sanz A.B., Sanchez-Nino M.D., Ortiz A. TWEAK, a multifunctional cytokine in kidney injury. Kidney Int. 2011, 80:708-718.
53. Sanz A.B., Sanchez-Nino M.D., Ramos A.M., Moreno J.A., Santamaria B., Ruiz-Ortega M., Egido J., Ortiz A. NF-kappaB in renal inflammation. J. Am. Soc. Nephrol. 2010, 21:1254-1262.
54. Sayyed S.G., Hagele H., Kulkarni O.P., Endlich K., Segerer S., Eulberg D., Klussmann S., Anders H.J. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 2009, 52:2445-2454.
55. Schlondorff D. Preparation and study of isolated glomeruli. Methods Enzymol. 1990, 191:130-140.
56. Schmid H., Boucherot A., Yasuda Y., Henger A., Brunner B., Eichinger F., Nitsche A., Kiss E., Bleich M., Grone H.J., Nelson P.J., Schlondorff D., Cohen C.D., Kretzler M. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006, 55:2993-3003.
57. Seok S.J., Lee E.S., Kim G.T., Hyun M., Lee J.H., Chen S., Choi R., Kim H.M., Lee E.Y., Chung C.H. Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice. Nephrol. Dial. Transplant. 2013, 28:1700-1710.
58. Shimizu H., Maruyama S., Yuzawa Y., Kato T., Miki Y., Suzuki S., Sato W., Morita Y., Maruyama H., Egashira K., Matsuo S. Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J. Am. Soc. Nephrol. 2003, 14:1496-1505.
59. Suzuki Y., Lopez-Franco O., Gomez-Garre D., Tejera N., Gomez-Guerrero C., Sugaya T., Bernal R., Blanco J., Ortega L., Egido J. Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1. Am. J. Pathol. 2001, 159:1895-1904.
60. Takano Y., Hiramatsu N., Okamura M., Hayakawa K., Shimada T., Kasai A., Yokouchi M., Shitamura A., Yao J., Paton A.W., Paton J.C., Kitamura M. Suppression of cytokine response by GATA inhibitor K-7174 via unfolded protein response. Biochem. Biophys. Res. Commun. 2007, 360:470-475.
61. Tarabra E., Giunti S., Barutta F., Salvidio G., Burt D., Deferrari G., Gambino R., Vergola D., Pinach S., Perin P.C., Camussi G., Gruden G. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 2009, 58:2109-2118.
62. Tesch G.H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2008, 294:F697-F701.
63. Viedt C., Dechend R., Fei J., Hansch G.M., Kreuzer J., Orth S.R. MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-kappaB and activating protein-1. J. Am. Soc. Nephrol. 2002, 13:1534-1547.
64. Wiggins J.E., Patel S.R., Shedden K.A., Goyal M., Wharram B.L., Martini S., Kretzler M., Wiggins R.C. NFkappaB promotes inflammation, coagulation, and fibrosis in the aging glomerulus. J. Am. Soc. Nephrol. 2010, 21:587-597.
65. Winkles J.A. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 2008, 7:411-425.
66. Xia Y., Campbell S.R., Broder A., Herlitz L., Abadi M., Wu P., Michaelson J.S., Burkly L.C., Putterman C. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin. Immunol. 2012, 145:108-121.
67. Zhao Z., Burkly L.C., Campbell S., Schwartz N., Molano A., Choudhury A., Eisenberg R.A., Michaelson J.S., Putterman C. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J. Immunol. 2007, 179:7949-7958.